Nouscom
Updated: November 04, 2026
CEO - Marina Udier
Country: Switzerland | Funding: €248.5M (+)
Founded: 2015
Website: https://nouscom.com/
Nouscom is a biotech company that develops a series of cancer-preventing vaccines that are capable of selectively killing tumor cells. It's flagship candidate - NOUS-209, an off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency and microsatellite instability. NOUS-209 uses two viral vectors to deliver 209 shared frameshift peptide neoantigens. The asset is designed to train the immune system to recognize and attack cancerous and precancerous cells before tumors develop.
Founded: 2015
Website: https://nouscom.com/
Nouscom is a biotech company that develops a series of cancer-preventing vaccines that are capable of selectively killing tumor cells. It's flagship candidate - NOUS-209, an off-the-shelf cancer immunotherapy that targets tumors with mismatch repair deficiency and microsatellite instability. NOUS-209 uses two viral vectors to deliver 209 shared frameshift peptide neoantigens. The asset is designed to train the immune system to recognize and attack cancerous and precancerous cells before tumors develop.
